Pyridine compounds as histamine H3 modulators

Details Pyridine compounds as histamine H3 modulators Pyridine compounds as histamine H3 modulators

2005-03-31

2008-09-09

Wilson, James O. (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Chalcogen in the nitrogen containing substituent

C544S358000

Reexamination Certificate

active

07423147

ABSTRACT:
Certain non-imidazole heterocyclic compounds are Histamine H3modulators in the treatment of Histamine H3receptor mediated diseases.

REFERENCES:
patent: 3538106 (1970-11-01), Hoffmann et al.
patent: 4792547 (1988-12-01), Itoh et al.
patent: 5780393 (1998-07-01), Newton
patent: 6201007 (2001-03-01), Ito et al.
patent: 6399607 (2002-06-01), Welch et al.
patent: 6645990 (2003-11-01), Askew et al.
patent: 2003/0125339 (2003-07-01), Chen et al.
patent: 2004/0224968 (2004-11-01), Seidelmann et al.
patent: 1051888 (1979-04-01), None
patent: 817911 (1951-10-01), None
patent: 1902694 (1969-09-01), None
patent: 2514334 (1987-10-01), None
patent: 0089153 (1983-09-01), None
patent: 0134096 (1985-03-01), None
patent: 0143630 (1985-06-01), None
patent: 1 388 535 (2004-02-01), None
patent: 1396487 (2004-03-01), None
patent: 44 020347 (1969-09-01), None
patent: 46 037595 (1971-11-01), None
patent: 06306051 (1994-11-01), None
patent: WO 84/04304 (1984-11-01), None
patent: WO 00/50391 (2000-08-01), None
patent: WO 00/76984 (2000-12-01), None
patent: WO 01/85715 (2001-11-01), None
patent: WO 03/37869 (2003-05-01), None
patent: WO 03/37891 (2003-05-01), None
patent: WO 03/66604 (2003-08-01), None
patent: WO 03/78398 (2003-09-01), None
patent: WO 03/82205 (2003-10-01), None
patent: WO 03/92686 (2003-11-01), None
patent: WO 2004/18428 (2004-03-01), None
patent: WO 2004/054973 (2004-07-01), None
patent: WO 2005/007644 (2005-01-01), None
patent: WO 2005/009976 (2005-02-01), None
patent: WO 2005/23247 (2005-03-01), None
LaVoie and patani. Chemical Reviews, 1996, 96, 3147-3176.
Vippagunta et al. Advanced Drug Delivery Reviews, 2001, 48, 3-26.
Akhundov et al., “Synthesis and Psychotropic Activity of Amides of 2-aminonicotinic Acid”,Khimiko-Farmatsevticheskki Zhurnal, vol. 20, No. 1 (1986) pp. 48-50, Rumoscow, Database Beilstein 1993, Database accession No. 5702704 (CNR) BRN: 5598995, 5632883, 5764929, 5774681, (XP002344011).
Buchi et al., “Syntheses of Some 2-Dialkylaminoalkoxy-6-alkylaminopyridines and 2-dialkylaminoalkylamino-6-alkoxypyridines”,Helvetica Chimica Acta., vol. 48, No. 5 (1965) pp. 1216-1219, Chverlag Helvetica Chimica Acta. Basel, (XP009050917).
Highfield et al., “Preparative, Physico-Chemical and Cytotoxicity Studies of Prodrugs Activated in Hyposiz to Give Metal-Binding Analogues of Bleomycin”,Journal of the Chemical Society, Perkin Transactions 1, vol. 16 (1999) pp. 2343-2352, GB Chemical Society, Letchworth, (XP002337176).
Pavia et al., “N,N-Disubstittuted 6-Alkoxy-2-Pyridinamines as Anticonvulsant Agents”,Journal of the American Chemical Society, vol. 30, No. 7 (1987) pp. 1210-1214, US American Chemical Society, Washington DC, (XP002337175).
Stark, “Recent Advances in Histamine H3/H4Receptor Ligands”,Expert Opinion on Therapeutic Patents, vol. 13, No. 6 (2003) pp. 851-865, Ashley Publications, GB, ISSN: 1354-3776, (XP002298271).
Thunus et al., “Quelques Derives de la (Methyl-4, Peperazinyl-1)-2 Pyridine Substituee en 3”,European Journal of Medicinal Chemistry, vol. 9, No. 1 (1974) pp. 55-58, Freditions Scientifique Elsevier, Paris, (XP009050898), No.
“Phenylalkynes to Treat Histamine-Mediated Conditions”,Expert Opinion on Therapeutic Patents, vol. 13, No. 11 (2003) pp. 1759-1762, Gbashley Publications, (XP002337280).
Arrang, J.-M. et al. Auto-inhibition of Brain Histamine Release Mediated by a Novel Class (H3) of Histamine Receptor.Nature1983, 302, 832-837.
Ash, A.S.F.; Schild, H.O. Receptors Mediating Some Actions of Histamine.Br. J. Pharmac. Chemother.1966, 27, 427-439.
Barnes, J.C. et al. The Selective Histamine H3 Receptor Antagonist Thioperamide Improves Cognition and Enhances Hippocampal Acetylcholine Release In Vivo.Soc. Neurosci. Abstr. 1993, 19, 1813.
Black, J.W. et al. Definition and Antagonism of Histamine H2-Receptors.Nature1972, 236, 385-390.
Ganellin, C.R. et al. Synthesis of Potent Non-Imidazole Histamine H3-Receptor Antagonists.Arch. Pharm. Pharm. Med. Chem.(Weinheim, Ger.) 1998, 331, 395-404.
Ichinose, M.; Barnes, P.J. Histamine H3-Receptors Modulate Nonadrenergic Noncholinergic Neural Bronchoconstriction in Guinea-Pig In Vivo.Eur. J. Pharmacol.1989, 174(1), 49-55.
Imamura, M. et al. Unmásking of Activated Histamine H3-Receptors in Myocardial Ischemia: Their Role as Regulators of Exocytotic Norepinephrine Release.J. Pharmacol. Exp. Ther.1994, 271(3), 1259-1266.
Krause, M. et al. Medicinal Chemistry of Histamine H3Receptor Agonists. InThe Histamine H3Receptor—A Target for New Drugs. Leurs, R.; Timmerman, H., Eds.; Elsevier: 1998; pp. 175-196.
Letavic, M.A. et al. Recent Medicinal Chemistry of the Histamine H3Receptor. Prog. in Med. Chem., in press.
Leurs, R. et al. The Medicinal Chemistry and Therapeutic Potentials of Ligands of the Histamine H3Receptor.Prog. Drug Res. 1995, 45, 107-165.
Lin, J.-S. et al. Involvement of Histaminergic Neurons in Arousal Mechanisms Demonstrated with H3-Receptor Ligands in the Cat.Brain Res.1990, 523, 325-330.
Linney, I.D. et al. Design, Synthesis, and Structure-Activity Relationships of Novel Non-Imidazole Histamine H3Receptor Antagonists.J. Med. Chem.2000, 43(12), 2362-2370.
Lovenberg, T.W. et al. Cloning and Functional Expression of the Human Histamine H3Receptor.Mol. Pharmacol.1999, 55(6), 1101-1107.
MacDonald, S.J.F. et al. Discovery of Further Pyrrolidine trans-Lactams as Inhibitors of Human Neutrophil Elastase (HNE) with Potential as Development Candidates and the Crystal Structure of HNE Complexed with an Inhibitor (GW475151).J.Med.Chem.2002, 45(18), 3878-3890.
Machidori, H. et al. Zucker Obese Rats: Defect in Brain Histamine Control of Feeding.Brain Res.1992, 590, 180-186.
Mase, T. et al. Synthesis of Muscarinic Receptor Antagonist via a Diastereoselective Michael Reaction, Selective Deoxyfluorination and Metal-Halogen Exchange Reaction.J. Org. Chem.2001, 66, 6775-6786.
McLeod, R.L. et al. Antimigraine and Sedative Activity of SCH 50971: A Novel Orally-Active Histamine H3Receptor Agonist.Soc. Neurosci. Abstr.1996, 22, 2010.
Monti, J.M. et al. Effects of Selective Activation or Blockade of the Histamine H3Receptor on Sleep and Wakefulness.Eur. J. Pharmacol.1991, 205(3), 283-287.
Morisset, S. et al. High Constitutive Activity of Native H3Receptors Regulates Histamine Neurons in Brain.Nature2000, 408, 860-864.
Panula, P. et al. Significant Changes in the Human Brain Histaminergic System in Alzheimer's Disease.Soc. Neurosci. Abstr.1995, 21, 1977.
Phillips, J.G. and S.M. Ali. Medicinal Chemistry of Histamine H3Receptor Antagonists. InThe Histamine H3Receptor—A Target for New Drugs.Leurs, R.; Timmerman, H., Eds.; Elsevier: 1998; pp. 197-222.
Reiner, J.E. et al. Non-Covalent Thrombin Inhibitors Featuring P3-Heterocycles with P1-Monocyclic Arginine Surrogates.Bioorg. Med. Chem. Lett.2002, 12, 1203-1208.
Schlicker, E.; Marr, I. The Moderate Affinity of Clozapine at H3Receptors Is Not Shared by Its Two Major Metabolites and by Structurally Related and Unrelated Atypical Neuroleptics.Naunyn-Schmiedeberg's Arch. Pharmacol.1996, 353, 290-294.
Stark, H. et al. Developments of Histamine H3-Receptor Antagonists.Drugs Future1996, 21(5), 507-520.
Tozer, M.J.; Kalindjian, S.B. Histamine H3Receptor Antagonists.Exp. Opin. Ther. Patents2000, 10(7), 1045-1055.
Turner, S.C. et al. A New Class of Histamine H3-Receptor Antagonists: Synthesis and Structure-Activity Relationships of 7,8,9, 10-Tetrahydro-6H-cyclohepta[b]quinolones.Bioorg. Med. Chem. Lett.2003, 13(13), 2131-2136.
Walczynski, K. et al. Non-Imidazole Histamine H3Ligans. Part I. Synthesis of 2-(1-Piperazinyl)- and 2-(Hexahydro-1H-1,4-diazepin-1-yl)benzothiazole Derivatives as H3-Antagonists with H1 Blocking Activities.Farmaco1999, 54, 684-694.
Walczynski, K. et al. Non-Imidazole Histamine H3 Ligands, Part 2: New 2-Substituted Benzothiazoles as Histamine H3 Antagonists. Arch. Pharm. Pharm. Med. Chem. (Weinheim, Ger.) 1999, 332, 389-398.
Yokoyama, H. et al. Effect of Thioperamide, a Histamine H3Receptor Antagonist, on Electrically Induced Convulsions in Mice.Eur. J. Pharmacol.1993

Affiliated with

Also associated with

Rating

Pyridine compounds as histamine H3 modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyridine compounds as histamine H3 modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridine compounds as histamine H3 modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3978649